Search research articles
Contact Us
Filters
Showing results (191-200 of 224) with videos related to
Page
of 23
Sort By:
BMJ (Clinical Research Ed.)
|
October 17, 2014
Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study
Ben Van Calster, Kirsten Van Hoorde, Lil Valentin, et al.
Gynecologic and Obstetric Investigation
|
February 13, 2022
The Risk of Endometrial Malignancy and Other Endometrial Pathology in Women with Abnormal Uterine Bleeding: An Ultrasound-Based Model Development Study by the IETA Group
Laure Wynants, Jan Yvan Jos Verbakel, Lil Valentin, et al.
BJU International
|
November 13, 2013
Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib
Benoit Beuselinck, Yann-Alexandre Vano, Stéphane Oudard, et al.
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics
|
January 19, 2022
Risk assessment for endometrial cancer in women with abnormal vaginal bleeding: Results from the prospective IETA-1 cohort study
Jan Yvan Verbakel, Ruben Heremans, Laure Wynants, et al.
The Oncologist
|
September 2, 2018
Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer
Kathleen Van Asten, Laurence Slembrouck, Siel Olbrecht, et al.
American Journal of Obstetrics and Gynecology
|
January 24, 2016
Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis group
Dirk Timmerman, Ben Van Calster, Antonia Testa, et al.
The Lancet. Oncology
|
May 12, 2019
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
Ignace Vergote, Giovanni Scambia, David M O'Malley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 18, 2010
Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis
Vanya Van Belle, Ben Van Calster, Olivier Brouckaert, et al.
The Lancet. Digital Health
|
June 3, 2025
Importance of sample size on the quality and utility of AI-based prediction models for healthcare
Richard D Riley, Joie Ensor, Kym I E Snell, et al.
NPJ Genomic Medicine
|
April 28, 2022
Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer
Adriaan Vanderstichele, Pieter Busschaert, Chiara Landolfo, et al.
Page
of 23
Search research articles
Search
Showing results (191-200 of 224) with videos related to
Sort By:
Page
of 23
BMJ (Clinical Research Ed.)
|
October 17, 2014
Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study
Ben Van Calster, Kirsten Van Hoorde, Lil Valentin, et al.
Gynecologic and Obstetric Investigation
|
February 13, 2022
The Risk of Endometrial Malignancy and Other Endometrial Pathology in Women with Abnormal Uterine Bleeding: An Ultrasound-Based Model Development Study by the IETA Group
Laure Wynants, Jan Yvan Jos Verbakel, Lil Valentin, et al.
BJU International
|
November 13, 2013
Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib
Benoit Beuselinck, Yann-Alexandre Vano, Stéphane Oudard, et al.
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics
|
January 19, 2022
Risk assessment for endometrial cancer in women with abnormal vaginal bleeding: Results from the prospective IETA-1 cohort study
Jan Yvan Verbakel, Ruben Heremans, Laure Wynants, et al.
The Oncologist
|
September 2, 2018
Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer
Kathleen Van Asten, Laurence Slembrouck, Siel Olbrecht, et al.
American Journal of Obstetrics and Gynecology
|
January 24, 2016
Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis group
Dirk Timmerman, Ben Van Calster, Antonia Testa, et al.
The Lancet. Oncology
|
May 12, 2019
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
Ignace Vergote, Giovanni Scambia, David M O'Malley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 18, 2010
Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis
Vanya Van Belle, Ben Van Calster, Olivier Brouckaert, et al.
The Lancet. Digital Health
|
June 3, 2025
Importance of sample size on the quality and utility of AI-based prediction models for healthcare
Richard D Riley, Joie Ensor, Kym I E Snell, et al.
NPJ Genomic Medicine
|
April 28, 2022
Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer
Adriaan Vanderstichele, Pieter Busschaert, Chiara Landolfo, et al.
Page
of 23